Health and economic impact at a population level of both primary and secondary preventive lung cancer interventions: A model-based cost-effectiveness analysis

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Health and economic impact at a population level of both primary and secondary preventive lung cancer interventions: A model-based cost-effectiveness analysis

★ 2 Recommended by Dr Martin Frey, Faculty Member

Lung Cancer

Diaz M, Garcia M, Vidal C, Santiago A, Gnutti G, Gómez D, Trapero-Bertran M, Fu M, Lung Cancer Prevention LUCAPREV research group.

doi: 10.1016/j.lungcan.2021.06.027

Lung, Respiratory and Thoracic Cancer

Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking-A modelling study

Lung Cancer.

Tomonaga Y, Ten Haaf K, Frauenfelder T, Kohler M, Kouyos RD, Shilaih M, Lorez M, de Koning HJ, Schwenkglenks M, Puhan MA

doi: 10.1016/j.lungcan.

Gastrointestinal Cancer

Population-based SEER analysis of survival in colorectal cancer patients with or without resection of lung and liver metastases

BMC Cancer.

Siebenhüner AR, Güller U, Warschkow R

doi: 10.1186/s12885-020-6710-1.

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France

Lung Cancer.

Chouaid C, Bensimon L, Clay E, Millier A, Levy-Bachelot L, Huang M, Levy P

doi: 10.1016/j.lungcan.

Lung, Respiratory and Thoracic Cancer

Educational level, management and outcomes in small-cell lung cancer (SCLC): A population-based cohort study

Lung Cancer.

Tendler S, Holmqvist M, Wagenius G, Lewensohn R, Lambe M, De Petris L

doi: 10.1016/j.lungcan.2019.11.008.

Lung, Respiratory and Thoracic Cancer

Overdiagnosis in lung cancer screening - estimates from the German Lung Cancer Screening Intervention Trial

Int J Cancer.

González Maldonado S, Motsch E, Trotter A, Kauczor HU, Heussel CP, Hermann S, Zeissig SR, Delorme S, Kaaks R

doi: 10.1002/ijc.33295.

RECOMMENDED

COVID-19

The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study

★ 2 Recommended by Prof. Dr Christoph Renner, Faculty Member

Lancet Oncol.

Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R, Rachet B, Aggarwal A

doi: 10.1016/S1470-2045(20)30388-0.

Lung, Respiratory and Thoracic Cancer

Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers

J Thorac Oncol.

Chouaid C, Luciani L, LeLay K, Do P, Bennouna J, Perol M, Moro-Sibilot D, Vergnenègre A, de Pouvourville G

doi: 10.1016/j.jtho.2017.07.013.

Lung Cancer

Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.

1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.

Related content

Health and economic impact at a population level of both primary and secondary preventive lung cancer interventions: A model-based cost-effectiveness analysis

Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking-A modelling study

Population-based SEER analysis of survival in colorectal cancer patients with or without resection of lung and liver metastases

Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France

Educational level, management and outcomes in small-cell lung cancer (SCLC): A population-based cohort study

Overdiagnosis in lung cancer screening - estimates from the German Lung Cancer Screening Intervention Trial

The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study

Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers

Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.